Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.

Frank, Malene Støchkel; Bodtger, Uffe; Gehl, Julie; Ahlborn, Lise Barlebo

Frank, Malene Støchkel; Bodtger, Uffe; Gehl, Julie; Ahlborn, Lise Barlebo.

Afiliação

Frank MS; Department of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, Denmark.
Bodtger U; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Gehl J; Department of Respiratory Medicine, Zealand University Hospital, 4700 Naestved, Denmark.
Ahlborn LB; Institute for Regional Health Research, University of Southern Denmark, 5000 Odense, Denmark.

Cancers (Basel) ; 14(1)2021 Dec 28.

Article em En | MEDLINE | ID: mdl-35008297

Palavras-chave

NSCLC; genomic profiling; precision medicine; re-biopsy; resistance mechanisms; targeted treatment; therapeutic pressure

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pulmao Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google